Howard G. Welgus is Director of Arcutis Biotherapeutics, Inc.. Currently has a direct ownership of 180,339 shares of ARQT, which is worth approximately $1.68 Million. The most recent transaction as insider was on Jun 14, 2024, when has been sold 10,139 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 180K
5.96% 3M change
5.96% 12M change
Total Value Held $1.68 Million

Howard G. Welgus Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 14 2024
BUY
Grant, award, or other acquisition
-
10,139 Added 5.32%
180,339 Common Stock
Jun 04 2024
SELL
Open market or private sale
$80,100 $8.01 p/Share
10,000 Reduced 5.55%
170,200 Common Stock
Jun 04 2024
BUY
Exercise of conversion of derivative security
$16,800 $1.68 p/Share
10,000 Added 5.26%
180,200 Common Stock
May 31 2023
BUY
Grant, award, or other acquisition
-
4,375 Added 2.51%
170,200 Common Stock
Apr 17 2023
SELL
Open market or private sale
$118,745 $13.97 p/Share
8,500 Reduced 4.88%
165,825 Common Stock
Apr 17 2023
BUY
Exercise of conversion of derivative security
$14,280 $1.68 p/Share
8,500 Added 4.65%
174,325 Common Stock
Apr 06 2023
SELL
Open market or private sale
$102,085 $12.01 p/Share
8,500 Reduced 4.88%
165,825 Common Stock
Apr 06 2023
BUY
Exercise of conversion of derivative security
$14,280 $1.68 p/Share
8,500 Added 4.65%
174,325 Common Stock
Feb 15 2023
SELL
Open market or private sale
$144,330 $16.98 p/Share
8,500 Reduced 4.88%
165,825 Common Stock
Feb 15 2023
BUY
Exercise of conversion of derivative security
$14,280 $1.68 p/Share
8,500 Added 4.65%
174,325 Common Stock
Jan 17 2023
SELL
Open market or private sale
$116,620 $13.72 p/Share
8,500 Reduced 4.88%
165,825 Common Stock
Jan 17 2023
BUY
Exercise of conversion of derivative security
$14,280 $1.68 p/Share
8,500 Added 4.65%
174,325 Common Stock
Nov 15 2022
SELL
Open market or private sale
$68,094 $20.01 p/Share
3,403 Reduced 2.01%
165,825 Common Stock
Nov 15 2022
BUY
Exercise of conversion of derivative security
$1,713 $1.68 p/Share
1,020 Added 0.6%
169,228 Common Stock
Oct 04 2022
SELL
Open market or private sale
$121,740 $20.29 p/Share
6,000 Reduced 3.44%
168,208 Common Stock
Aug 15 2022
SELL
Open market or private sale
$148,800 $24.8 p/Share
6,000 Reduced 3.33%
174,208 Common Stock
Jul 18 2022
SELL
Open market or private sale
$146,400 $24.4 p/Share
6,000 Reduced 3.22%
180,208 Common Stock
Jun 01 2022
SELL
Open market or private sale
$51,550 $20.62 p/Share
2,500 Reduced 1.36%
181,896 Common Stock
Jun 01 2022
BUY
Grant, award, or other acquisition
-
4,312 Added 2.26%
186,208 Common Stock
Jun 01 2022
BUY
Exercise of conversion of derivative security
$4,200 $1.68 p/Share
2,500 Added 1.34%
184,396 Common Stock
May 02 2022
SELL
Open market or private sale
$51,100 $20.44 p/Share
2,500 Reduced 1.36%
181,896 Common Stock
May 02 2022
BUY
Exercise of conversion of derivative security
$2,825 $1.13 p/Share
2,500 Added 1.34%
184,396 Common Stock
Apr 01 2022
SELL
Open market or private sale
$150,150 $20.02 p/Share
7,500 Reduced 3.96%
181,896 Common Stock
Apr 01 2022
BUY
Exercise of conversion of derivative security
$4,350 $0.58 p/Share
7,500 Added 3.81%
189,396 Common Stock
Jan 03 2022
SELL
Open market or private sale
$53,025 $21.21 p/Share
2,500 Reduced 1.36%
181,896 Common Stock
HGW

Howard G. Welgus

Director
Westlake Village, CA

Track Institutional and Insider Activities on ARQT

Follow Arcutis Biotherapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ARQT shares.

Notify only if

Insider Trading

Get notified when an Arcutis Biotherapeutics, Inc. insider buys or sells ARQT shares.

Notify only if

News

Receive news related to Arcutis Biotherapeutics, Inc.

Track Activities on ARQT